Disruption of ACTR5 (or its complex partner IES6) synergizes with pharmacological targeting of CDK4/6, providing critical rationales toward a more effective combinatorial therapy against HCC and beyond. The gene discussed is CDK4; the disease is hepatocellular carcinoma.